15 results
Thumbnail

D3.230 - Type I Hypersensitivity Among Private Dental Practitioners: Clinical Manifestations and Associated Factors

Thumbnail

D3.220 - Real-World Management of Pediatric Allergic Diseases: A Nationwide Physician Survey among Allergists and Pediatric Allergists in Turkey

Thumbnail

D3.215 - Shifting patterns of mite sensitization in Southern Europe: Real-World diagnostic and immunotherapy practices in Spain and Portugal (MITE-WISE Project)

Thumbnail

D3.218 - When the sting is not the sensitizer: a vespid venom allergy case

Thumbnail

D3.223 - Crossroads of Venom and Bite: A case of Horsefly - Wasp Cross - reactive Anaphylaxis

Thumbnail

D3.225 - Two years Sublingual SQ-Grass Pollen Tablet Immunotherapy Combined with Dupilumab Induces Longterm Suppression of Immediate Cutaneous Allergen Sensitivity

Thumbnail

D3.229 - Comparison of mold sensitization profiles in children (2021 and 2025): impact of environmental deterioration during martial law

Thumbnail

D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset

Thumbnail

D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study

Thumbnail

D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes

Thumbnail

D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria

Thumbnail

D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project

Thumbnail

D3.427 - Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child

Thumbnail

D3.428 - Substratification of Biologic Treatment Using Dupilumab in Eosinophilic COPD

Thumbnail

D3.417 - Dupilumab in pediatric patients with severe atopic dermatitis